Dr. Ghafoor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8600 Old Georgetown Road
Bethesda, MD 20814Phone+1 301-896-7610Fax+1 301-896-7626
Education & Training
Ascension St Vincent Hospital IndianapolisResidency, Internal Medicine, 2013 - 2016
Indiana University School of MedicineClass of 2013
Certifications & Licensure
MD State Medical License 2016 - 2026
DC State Medical License 2016 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib Start of enrollment: 2016 Apr 13
- LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2019 Sep 11
Publications & Presentations
PubMed
- Multiple Onychopapillomas and BAP1 Tumor Predisposition Syndrome.Alexandra Lebensohn, Azam Ghafoor, Luke Bloomquist, Michael C Royer, Leslie Castelo-Soccio
JAMA Dermatology. 2024-08-01 - 26 citationsMesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results.Raffit Hassan, Marcus Butler, Roisin E O'Cearbhaill, David Y Oh, Melissa Johnson
Nature Medicine. 2023-08-01 - Somatic BAP1 Loss as a Predictive Biomarker of Overall Survival in Patients With Malignant Pleural Mesothelioma Treated With Chemotherapy.Azam Ghafoor, Raffit Hassan
Journal of Thoracic Oncology. 2022-07-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
